Outcome of patients (pts) with brain metastases (BMs) from HER2-positive breast cancer (BC) treated with lapatinib plus capecitabine (LC).
Giulio Metro(University of Perugia), Stefania Gori(Ospedale Sacro Cuore Don Calabria), Alessandra Fabi(Agostino Gemelli University Polyclinic), L. Crinò, Michelangelo Russillo(National Cancer Institute), Paola Papaldo(Cancer Institute (WIA)), Diana Giannarelli(Agostino Gemelli University Polyclinic), F. Cognetti(Sapienza University of Rome), Jennifer Foglietta, Lucia Stocchi(Ospedale Infermi di Rimini)
Cited by 1
Related Papers
Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab
|Annals of Oncology|2016|398
CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer
|Journal of Clinical Oncology|2015|253
Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab
|Clinical Cancer Research|2019|240